Funding for this trial has been provided in full or in part by Cystic Fibrosis Foundation Therapeutics, Inc.
Number of Participants Being Recruited:
Single / Multi-Center:
STUDY BACKGROUND INFORMATION:
Individuals with CF suffer from intermittent exacerbations of their disease, which is characterized by increased symptoms and drop in lung function. It is not clear that an individual who presents with mildly increased symptoms or a small drop in lung function should be treated with antibiotics nor how long antibiotics should be given when patients are treated for an exacerbation. This trial will measure biomarkers in blood, sputum, and exhaled breath at baseline and during the course of an exacerbation to to determine if biomarkers can be used to identify individuals who would benefit from initiation of antibiotic therapy as well as benefit from prolonged courses of antibiotics.
>= 14 Years
>= 25 Percent Predicted
P. aeruginosa status:
B. cepacia status:
Other Primary Eligibility Requirements:
Note: Detailed eligibility criteria information may be available on clinicaltrials.gov. If a specific
trial listing for this trial is available, a link to the specific clinicaltrials.gov listing will be present in the "More Information" section below.
The sites listed below are currently recruiting subjects. Please note that this list generally lists either the pediatric or adult program but not both even though both programs may be recruiting subjects. Also, this list does not include sites that may be participating in the study but are not yet open for recruitment. If you are interested in this study please contact your center for more information.